Erratum to: Concept Mapping to Define Components for an Occupation-Based Intervention for Parkinson’s Disease and Anxiety

2024-9-9

Winding Back the Clock on Advanced Therapies: It’s Time to Get Smart

2024-9-6

Prospective Study of Lung Function with Prodromal, Clinical Parkinson’s Disease, and Mortality

2024-9-6

Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson’s Disease

2024-9-5

Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials

2024-9-3

“Tip-of-the-Tongue” Phenomenon in Parkinson’s Disease: A Hidden Gem

2024-9-3

Molecular Variability in Levodopa Absorption and Clinical Implications for the Management of Parkinson’s Disease

2024-8-31

Advice to People with Parkinson’s in My Clinic: Probiotics and Prebiotics

2024-8-23

Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson’s Disease

2024-8-22

The Associations Among Gut Microbiota, Branched Chain Amino Acids, and Parkinson’s Disease: Mendelian Randomization Study

2024-8-20

Post-Traumatic Stress Disorder and Risk of Parkinson’s Disease in a Veteran Cohort

2024-8-20

Stemming the Tide: The Proactive Role of Allied Health Therapy in Parkinson’s Disease

2024-8-13

Remote Delivery of Allied Health Therapies in Parkinson’s Disease

2024-8-13

Special Issue: Non-Pharmacological Interventions for People with Parkinson’s Disease: Are We Entering a New Era?

2024-8-13

Specialized Allied Health Care for Parkinson’s Disease: State of the Art and Future Directions

2024-8-13

Patient Empowerment for Those Living with Parkinson’s Disease

2024-8-9

A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders

2024-8-6

Which Gait Tasks Produce Reliable Outcome Measures of Freezing of Gait in Parkinson’s Disease?

2024-8-6

Advice to People with Parkinson’s in My Clinic: Orthostatic Hypotension

2024-8-1

Digital Intervention Promoting Physical Activity in People Newly Diagnosed with Parkinson’s Disease: Feasibility and Acceptability of the Knowledge, Exercise-Efficacy and Participation (KEEP) Intervention

2024-7-30

Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain

2024-7-23

A Randomized Controlled Trial of Fecal Microbiota Transplantation for Parkinson’s Disease: Getting it right, if not PARFECT

2024-7-23

Erratum to: CiteSerum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study

2024-7-23

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update

2024-7-23

Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson’s Disease

2024-7-23

Development of a Screening Tool for Assessing Sexual Difficulties Among Patients with Parkinson’s Disease: The PD-SDS

2024-7-23

Reply to the Letter to the Editor: Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”

2024-7-23

Letter to the Editor: Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same?

2024-7-23

Mycobacterium bovis Infection of a Deep Brain Stimulation System Following Intravesical Bacillus Calmette-Guérin (BCG) Instillation

2024-7-23

Risk Factors for Postoperative Delirium Severity After Deep Brain Stimulation Surgery in Parkinson’s Disease

2024-7-20

Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials

2024-7-20

The AAV-α-Synuclein Model of Parkinson’s Disease: An Update

2024-7-19

Exposure to Glycolysis-Enhancing Drugs and Risk of Parkinson’s Disease: A Meta-Analysis

2024-7-19

Considerations on How to Prevent Parkinson’s Disease Through Exercise

2024-7-17

Data-Driven Subtypes of Multiple System Atrophy and Their Implications for Prognosis

2024-7-17

Are Preformed Fibrils a Model of Parkinson’s Disease?

2024-7-12

Diabetes and Parkinson’s Disease: Understanding Shared Molecular Mechanisms

2024-7-12

Biofluid Detection of Pathological α-Synuclein in the Prodromal Phase of Synucleinopathies

2024-7-10

How Information Affects Patients with Parkinson’s Disease: A Scoping Review of the Literature

2024-7-8

Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review

2024-7-4

Unmet Need in Early-Onset Parkinson’s Disease: Deep Brain Stimulation and Pregnancy

2024-7-4

Progressive Supranuclear Palsy: Subcortical Tau Depositions Are Associated with Cortical Perfusion in Frontal and Limbic Regions

2024-7-4

Natural Health Products for Symptomatic Relief of Parkinson’s Disease: Prevalence, Interest, and Awareness

2024-6-28

Rapid Voluntary Blinking as a Clinical Marker of Parkinson’s Disease

2024-6-26

Non-Pharmacological Interventions for People with Parkinson’s Disease: Are We Entering a New Era?

2024-6-25

Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease

2024-6-18

Impact of Physical Exercise on Levodopa Therapy Across Parkinson’s Disease Stages

2024-6-16

How Parkinson’s Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types

2024-6-15

Gait Analysis with Wearable Sensors in Isolated REM Sleep Behavior Disorder Associated with Phenoconversion: An Explorative Study

2024-6-7

Disease Progression of Data-Driven Subtypes of Parkinson’s Disease: 5-Year Longitudinal Study from the Early Parkinson’s disease Longitudinal Singapore (PALS) Cohort

2024-6-7